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Available online 9 December 2015Aims: Interleukin-10 (IL-10) is a multi-functional cytokine with potent anti-inﬂammatory properties. We hy-
pothesized that IL-10 limits increased RhoA/Rho-kinase signaling and vascular reactivity in arteries from angio-
tensin II (Ang II) hypertensive mice.
Mainmethods:Wild type (WT) and IL-10 knockout (−/−) micewere infusedwith Ang II (90 ng/min) for 14 days.
Additionally, WT mice were infused with Ang II and simultaneously infused with exogenous IL-10 (0.5 ηg/min,
14 days). Aortic rings were mounted in a myograph and concentration-response curve to phenylephrine (PE)
were evaluated.
Key ﬁndings: After Ang II infusion, blood pressure responses, but notmaximal contraction to PE, was greater in IL-
10−/− mice, compared to WT. Rho-kinase inhibition (Y-27632; 10 μM) resulted in a more evident reduction of
PE-induced contraction in WT hypertensive mice, when compared to IL-10−/− hypertensive mice. IL-10 exoge-
nous infusion prevented the blood pressure increase in Ang II-infused WT mice. The augmented PE-contraction
observed in aorta fromWTmice infusedwith Ang IIwas also prevented by exogenous infusion of IL-10. Addition-
ally, Rho-kinase inhibition (Y-27632; 10 μM) abolished the differences in the contractile response to PE between
these groups.
Signiﬁcance: These results demonstrate that IL-10 counteracts both the pressoric activity of Ang II as well as vas-
cular dysfunction associated with hypertension, partially, modulating the RhoA-Rho kinase pathway. Strategies
to enhance IL-10 levels during hypertension may enhance the beneﬁts provided by regular treatments.
© 2015 Elsevier Inc. All rights reserved.Keywords:
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Low-grade inﬂammation is a player on the pathophysiology of
cardiovascular diseases. In this regard, it has been established that
increased production of pro-inﬂammatory cytokines, such as inter-
leukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α), modulates
vascular function by increasing contractile pathways and also, by
decreasing endothelium-dependent vascular relaxation through
distinct mechanisms [1].
Interleukin-10 (IL-10) is a multi-functional cytokine with potent
anti-inﬂammatory properties. The main function of IL-10 is to limit
and terminate inﬂammatory responses, by inhibiting a broad array of
immune parameters [2,3]. During the course of inﬂammation, IL-10 isrosso, Institute of Biological and
8600-000, Brazil.
iachini).produced by type 2 helper (Th2) T cells, B cells, monocytes and macro-
phages [2].
Stimulation of vascular smoothmuscle cell (VSMC)with angiotensin
II (Ang II) promotes pro-inﬂammatory injury in the vasculature,
by mechanisms related with the increased production of pro-
inﬂammatory cytokines,whereas the release of anti-inﬂammatory cyto-
kines, such as IL-10, is reduced [4–7]. Interestingly, it was found that
when hypertensive patients were treated with drugs that interfere
with Ang II actions, such as Ang II receptor 1 (AT1) receptor antagonists
or Ang II-converting enzyme (ACE) inhibitors, serum IL-10 levels were
augmented, compared to untreated hypertensive patients [3,8,9].
These ﬁndings suggest the interplay between Ang II and IL-10 during
hypertension.
It was shown that IL-10 improves endothelium-dependent relaxa-
tion by inhibiting NADPH oxidase activity in Ang II-hypertensive rats,
improving their blood pressure [10]. However, the direct interplay be-
tween IL-10 and VSMC contractility during hypertension remains an
unexplored area.
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in increased vascular contractility, a hallmark of hypertension [11,12].
Increased contraction in VSMC, induced by Ang II, has been associated
with enhanced activation of the RhoA/Rho-kinase signaling pathway,
a system which regulates calcium-sensitization. In fact, a role for en-
hanced RhoA/Rho kinase activity has been reported both in experimen-
tal and clinical hypertension [11,13].
As previously mentioned, Ang II promotes pro-inﬂammatory injury
in the vasculature and the antagonism of its action lowers blood pres-
sure, improves vascular function and elevates serum levels of IL-10
[9]. Considering these evidences, we hypothesized that IL-10 therapy
limits increased RhoA/Rho-kinase signaling in arteries from Ang II-hy-
pertensive mice, improving both increased vascular contractility and
augmented blood pressure during hypertension.
The overall strategywas to evaluate the endogenous and exogenous
role of IL-10 actions in the blood pressure regulation and vascular con-
tractile function in Ang II-hypertensive mice.2. Methods
2.1. Animals
Male B6.129P2-Il10tm1Cgn/J (IL-10−/−)mice and their control C57BL/
6 J mice [wild type (WT), The Jackson Laboratory, Maine, US], with 10–
12weeks,were used in this study. All procedureswere performed in ac-
cordancewith theGuiding Principles in the Care andUse of Animals, ap-
proved by the Georgia Health sciences university Committee on the Use
of Animals in Research and Education. The animals were housed four
per cage on 12-h light/dark cycle and fed a standard chow diet with
water ad libitum. Animals were anesthetized with isoﬂurane via a
nose cone for surgical procedures (initially with 5% and then main-
tained at 2.0% in 100% oxygen). Osmotic mini pumps (0.25 μl per hour
– 14 days – model 1002, Alzet Co., Cupertino, CA) were implanted
subcutaneously.
The ﬁrst set of experiments was designed to evaluate the role of en-
dogenous IL-10 in hypertensivemice. Therefore, IL-10−/− andWTmice
were infused with vehicle only (saline) or with Ang II (90 ηg ⋅min−1)
for a period of 14 days.
The second set of experiments was designed to evaluate the role of
exogenous IL-10 in hypertensive mice. C57BL/6 J mice were infused
with vehicle (saline) or Ang II (90 ng.min−1), and simultaneously in-
fused (additional mini-pump), with or without recombinant mouse
IL-10 (0.5 ηg.min−1), for a period of 14 days.
In these two sets of experiments, mean arterial pressure was
assessed by catheterization, as described following.2.2. Blood pressure recording
At the end of experiment mice were anesthetized with isoﬂurane
via a nose cone for surgical procedures (initially with 5% and then
maintained at 2.0% in 100% oxygen). Following anesthesia, a sterile
catheter PE-10 tube was inserted into the carotid artery. The incision
was closed with a sterile 6–0 Ethicon Ophthalmic suture. The cathe-
ter was secured on the back of the mouse to avoid any biting of the
tube by the mouse. All surgeries were conducted under aseptic and
sterile conditions to avoid any chances of infection. Mice received
one unique dose of tromethamine (1 g ⋅kg−1 i.m.) after the surgery.
Once the mouse had completely recovered from anesthesia and
from the stress manipulation (2 h after surgery), the catheter was
connected to a transducer to record mean arterial pressure. Record-
ing measurements of mean arterial pressure were made for 3 to 4 h.
Subsequently, blood was collected and the mice were killed in a CO2
chamber, and the aorta was isolated for functional and molecular
studies.2.3. Vascular functional studies
Thoracic aortas were rapidly excised and placed in ice-cold physio-
logical salt solution (PSS), and carefully dissected. Endotheliumwasme-
chanically removed by rubbing the artery with a metallic pin. Aortas
were mounted as ring preparations (4 mm in length) in standard
organ chambers for isometric tension recording by a PowerLab 8/SP
data acquisition system (ADInstruments Pty Ltd., Colorado Springs,
CO). The segments were adjusted to maintain a passive force of 5 mN.
Aortas were equilibrated for 60 min in PSS at 37 °C, and continuously
bubbledwith amix of 5% CO2 and 95%O2. Arterial integritywas assessed
by stimulation of vessels with high potassium solution (KCl, 120 mM).
After washing and a new stabilization, the absence of endothelium
was assessed by contracting the segments with phenylephrine (PE;
1 μM) followed by acetylcholine (ACh; 10 μM). The absence of a
relaxation-response to ACh stimulation was taken as evidence of endo-
thelium removal. Concentration-response curve to PE (1 nM to 100 μM)
were performed in presence or absence of Y27632 (10 μM, 40 min), a
Rho kinase inhibitor.
2.4. Western blot Analysis
Proteins (40 μg) extracted from aorta were separated by electropho-
resis on a 10% polyacrylamide gel and transferred to a nitrocellulose
membrane. Nonspeciﬁc binding sites were blocked with 5% skim milk
in Tris-buffered saline solution with Tween (TBS-T) for 1 h at 24 °C.
Membranes were then incubated with primary antibodies overnight
at 4 °C. Antibodies were as follows: RhoA (Abcam, 1:1000), ROCK-α
and ROCK-β (BD Transduction, 1:500). On next day membranes were
removed from primary antibodies and washed with TBS-T. Membranes
were treated with secondary antibody for one hour. After incubation
with respective secondary antibodies, signals were visualized using
chemiluminescence and images were captured using Alpha Imager
from Alpha Innotech (San Leandro, CA). All blots were stripped and
probed with anti-β-actin antibody (Sigma, 1:20,000), to ensure equal
protein loading. Results were normalized to β-actin protein and
expressed as arbitrary units.
2.5. IL-10 level
Plasmatic level of mouse IL-10 was determined by sandwich
enzyme-linked immunosorbent assay (ELISA) kit (R & D Systems, Min-
neapolis, MN).
2.6. Drugs and solutions
Physiological salt solution (PSS) of the following composition was
used: 130 mM NaCl, 14.9 mM NaHCO3, 4.7 mM KCl, 1.18 mM KH2PO4,
1.17 mM MgSO4·7H2O, 5.5 mM glucose, 1.56 mM CaCl2·2H2O and
0.026 mM EDTA. Ang II was purchased from Phoenix Pharmaceutical
Inc. (Burlingame, CA). Recombinant mouse IL-10 was purchased by BD
Bioscience (San Jose, California). PE and ACh were purchased from
Sigma Chemical Co. (St. Louis, MO). Y-27632was purchased from Tocris
(Ellisville, MO). All reagents were of analytical grade. Stock solutions
were prepared in ultrapure water or saline (Ang II and IL-10).
2.7. Data analysis
Results are presented as mean± standard error of the mean (SEM).
Contractions were recorded as changes in the displacement (mN) from
baseline, normalized by KCl contraction and are represented as percent-
age of KCl-induced contraction, for n experiments. Concentration-
response curves were ﬁtted using a nonlinear interactive ﬁtting pro-
gram. Curve-ﬁt parameters were used to ﬁt a sigmoid curve and two
pharmacological parameters were obtained: the maximal effect gener-
ated by the agonist (or Emax) and -log EC50 (or pD2). Statistical
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Bonferroni post-hoc analysis to compare the concentration-responses
curves between all the groups. Statistically signiﬁcant differences were
calculated by ANOVA. Values of p b 0.05 were considered a statistically
signiﬁcant difference.
3. Results
3.1. Effect of IL-10 and Ang II on blood pressure
After 14 days, Ang II infusion augmented mean arterial pressure
[MAP (mmHg)] both in WT and IL-10−/− mice. However, changes in
MAP after Ang II infusion was greater in IL-10−/− mice, compared to
WT. No differences were observed in MAP between in vehicle-infused
WT or vehicle-infused IL-10−/− mice.
Exogenous IL-10 infusion did not result in signiﬁcant MAP changes
in WT mice, after 14 days. However, mice infused simultaneously with
exogenous IL-10 and Ang II showed reduced MAP, compared to WT
mice infused with Ang II or IL-10−/−mice infused with Ang II (Fig. 1A).
After 14 days, plasma IL-10 levels (pg ⋅mL−1) were smaller in Ang II-
infused WT mice, compared to vehicle-infused WT mice (4.9 ± 2.3 vs.
10.6 ± 1.5, respectively). Exogenous IL-10 infusion increased plasma
IL-10 levels both in vehicle-infused WT (18.3 ± 2.8) and in Ang II-
infused WT mice [24.4 ± 2.3; (Fig. 1B)].
3.2. Effect of IL-10 on PE-induced vasoconstriction
Aortas from Ang II-infused WT mice displayed augmented PE-
induced contraction, compared to vehicle-infused WT mice [Emax
212 ± 9 vs. 175 ± 9%, respectively; (Fig. 2A)].
Ang II-infused IL-10−/− mice displayed augmented PE-induced
contraction (Emax 225 ± 6%) when compared to vehicle-infused
IL-10−/−mice [Emax 189± 8%; (Fig. 2B)]. No differences were observedFig. 1. IL-10prevents Ang II pressure response. A)Meanarterial pressure changes uponve-
hicle or Ang II infusion observed in WT mice, IL-10−/−mice or WT mice infused with ex-
ogenous IL-10 after 14 days (n = 5–9). B) IL-10 plasma levels in WT mice infused or not
with Ang II for 14 days, with or without simultaneous infusion of exogenous IL-10 (n =
6). * P b 0.05 vs. respective vehicle; ‡ P b 0.05 vs. WT + vehicle; † P b 0.05 vs. WT + Ang
II and ♦ vs. respective IL-10 −/− group.
Fig. 2. Effect of IL-10 on PE-induced contractile response in aorta formAng II-infusedmice.
Contractile response in aorta from mice infused (closed symbols) or not (open symbols)
with Ang II: A) WT mice; B) IL-10−/− mice; C) WT mice infused with exogenous IL-10;
(n = 6–10)* P b 0.05 vs. respective vehicle.in PE-contractile response between aortas fromWT and IL-10−/− mice
infusedwith vehicle suggesting that, physiologically, contractile proper-
ties are not affected in thesemice. Ang II-infused IL-10−/−mice showed
augmented sensitivity to PE compared to Ang II-infused WT mice
(Table 1). No differences were observed in KCl-induced contraction be-
tween groups.
Augmented PE-induced contraction persisted in aortas fromWT co-
infused with exogenous IL-10 and Ang II (Emax 167 ± 5%), when com-
pared to aortas from WT infused exclusively with exogenous IL-10
[(Emax 139 ± 3%), Fig. 2B]. However, exogenous IL-10 infusion de-
creased PE-induced contraction, when compared to aortas from WT
mice infused with vehicle (Table 1). Additionally, when exogenous IL-
10 was simultaneously infused with Ang II, a smaller contractile re-
sponse to PE was observed, when compared to aortas fromWTmice in-
fused with Ang II alone (Table 1).
In order to investigate if IL-10decreases PE-contraction bymodulating
the RhoA/Rho kinase pathway, incubations with a Rho kinase inhibitor
(Y-32627, 10 μM) were performed.
Under Rho-kinase inhibition condition, maximum contraction to PE
were reduced both in Ang II and vehicle-infused WT mice (Emax 115 ±
Table 1
Emax (%KCl) and pD2 values for phenylephrine induced contraction in the presence or ab-
sence of Y-27632.
Y-27632
KCl
(mN)
Emax pD2 Emax pD2
WT + vehicle 7,1 ± 0.4 175 ± 9 7.1 ± 0.1 121 ± 14 6.7 ± 0.3
WT + Ang II 7,0 ± 0.5 212 ± 9* 7.4 ± 0.2* 115 ± 20 6.8 ± 0.6
IL-10−/− + vehicle 7,3 ± 0.8 189 ± 8 7.8 ± 0.4‡ 114 ± 18 7.2 ± 0.3‡
IL-10−/− + Ang II 7,2 ± 0.8 225 ± 6* 7.7 ± 0.2† 156 ± 06*† 6.7 ± 0.4 *
WT + IL-10 7,0 ± 0.3 139 ± 3‡ 7.2 ± 0.1 57 ± 10‡ 6.6 ± 0.2
WT + IL-10 + Ang
II
7,3 ± 0.6 167 ± 5* † 7.1 ± 0.1† 73 ± 06† 6.7 ± 0.2
Concentration-response curves to phenylephrine (PE) and single stimulation with high
potassium solution (KCl, 120 mM) were performed in aorta from mice, in the absence or
in the presence of Y-27632 (10 μmol/L, for 40 min). Data are mean ± SEM (n= 6). * P b
0.05 vs. respective vehicle group; † P b 0.05 vs. WT + Ang II; ‡ P b 0.05 vs. WT + vehicle.
Fig. 3. IL-10 decreased contraction in aorta form Ang II-infused mice through rho kinase-
dependent mechanism. Contractile response in aorta frommice infused (closed symbols)
or not (open symbols) with Ang II, in the presence of the rho kinase inhibitor, Y-27632
(10 μM): A) WT mice; B) IL-10−/− mice; C) WT mice infused with exogenous IL-10;
(n = 5–6). * P b 0.05 vs. respective vehicle.
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tween these groups were abolished after Rho-kinase inhibition (Fig. 3A).
Aortas from Ang II- or vehicle-infused IL-10−/−mice incubatedwith
Rho-kinase inhibitor resulted in smaller PE-induced contraction in both
groups (Emax 156 ± 6 vs. 114 ± 18%, respectively). However, Rho-
kinase inhibition was not able to completely abolish differences in the
contractile response to PE observed in aortas from Ang II-infused IL-
10−/− mice, compared to vehicle-infused IL-10−/− mice (Fig. 3B).
In addition, after Rho-kinase inhibition, PE-induced contractions
were further reduced in aortas from WT mice infused simultaneously
with Ang II and exogenous IL-10 or only infused with IL-10 (73 ± 6
vs. 57 ± 10%, respectively). In this case, differences between these
groups were abolished after Rho-kinase inhibition (Fig. 3C).
3.3. Effect of IL-10 on RhoA and Rho kinases protein expression
RhoA expression was increased after Ang II infusion, both in aortas
from WT or IL-10−/− mice, when compared to their respective
vehicle-infused control. WT mice infused with Ang II did not display
changes on ROCK-α expression. However, ROCK-α expressionwas aug-
mented in aortas from IL-10−/− mice infused with Ang II or vehicle.
ROCK-βwas augmented in aortas from Ang II-infusedWTmice. The ex-
pression of ROCK-βwas further increased in aortas from IL-10−/−mice,
especially after Ang II infusion (Fig. 4A).
Expression of RhoA was greater in aortas from Ang II-infused WT
mice, compared to vehicle-infused WT mice. Simultaneous infusion of
Ang II and IL-10 inWTmice prevented RhoA increased expression. Fur-
thermore, infusion of IL-10 alone did not change RhoA expression. IL-10
exogenous infusion or Ang II infusion did not affect expression of ROCK-
α. However, IL-10 simultaneously infused with Ang II in WT mice
prevented the augmented expression of ROCK-β, which was observed
in aortas from Ang II-infused WT mice (Fig. 4B).
4. Discussion
Themajorﬁndings of this studywere: (1) endogenous IL-10 contrib-
utes to blood pressure regulation under Ang II infusion; (2) exogenous
IL-10 infusion was effective to increase IL-10 circulating levels and
was able to prevent Ang II-pressoric actions, but did not affect blood
pressure control in physiological conditions; (3) under Ang II infusion,
the absence of IL-10 resulted in increased contractile response to PE,
and in WT mice, exogenous infusion of IL-10 prevented increased con-
traction in aortas from Ang II-infused mice; (4) increased response to
PE in aortas from Ang II-infusedmice were decreased by Rho-kinase in-
hibition and (6) IL-10 seems to negatively modulate RhoA/Rho kinase
expression.
Initially, we aimed to further investigate if IL-10 regulates blood
pressure. To test this, we used the Ang II-hypertension model. Ang II
regulates blood pressure by several mechanisms including vasocon-
striction, release of reactive oxygen species, production of pro-
inﬂammatory mediators, among others [12]. Using direct blood pres-
sure measurement, we observed that IL-10 knockout mice displayed
similar MAP at basal condition, compared to their respective control
mice. These results are in agreement with recent studies, where systolic
blood pressure was measured in conscious mice using tail-cuff [10,14].
Upon Ang II infusion, changes inmean arterial pressurewere greater
in IL-10 knockout mice, compared to control mice, showing that endog-
enous IL-10 limits Ang II-pressoric effect. In addition, exogenous IL-10
infusion was able to prevent increases in blood pressure after Ang II in-
fusion. Kassan and colleagues observed similar effects in diastolic blood
pressure, where Ang II-hypertensive rats were simultaneously infused
with exogenous IL-10 (1000 ng/mouse, for 14 days). They attribute
that IL-10 prevents the pressor effects of Ang II, mainly by inhibiting ac-
tivation of NADPH oxidase and by improving nitric oxide bioavailability,
and therefore, by improving endothelial function [10].
Fig. 4.Vascular expression of RhoA and rho kinasesα andβ ismodulated by IL-10. RhoA, ROCK-α and ROCK-β expression in aortas frommice infused or notwith Ang II: A)WTmice and IL-
10−/−mice; B) WT mice infused with or without exogenous IL-10; (n = 5–6). * P b 0.05 vs. respective vehicle; ‡ P b 0.05 vs. WT + vehicle; † P b 0.05 vs. WT + Ang II.
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control, we decided to evaluate other pathways modulated by IL-10,
with potential protective activity both in vascular function and in
blood pressure regulation. Our results demonstrated increased vascular
contractile response to PE, in aortas from hypertensive mice. Themech-
anisms responsible to elevate vascular contractile responsiveness in hy-
pertension are complex. However, it is clear that the balance in cellular
signaling mechanisms that promote contraction and relaxation of vas-
cular smooth muscle cells is disrupted to favor vasoconstriction and
the increased peripheral resistance is caused, in part, by an alteration
in vascular smoothmuscle thatmakes it more sensitive to normal stim-
uli [11], contributing to augmented blood pressure.
The protective role of IL-10 on the vascular function was initially
demonstrated, addressing mostly the protective effect of this cytokine
in the endothelial function. It was shown that IL-10 knockout mice,
upon Ang II infusion, displays decreased endothelium-dependent relax-
ation, mainly due to augmented oxidative stress production [14]. Here,
we show a direct effect of Il-10 on vascular smooth muscle cells. We
showed that upon Ang II infusion, absence of endogenous IL-10 resulted
in augmented vascular constriction; whereas exogenous IL-10 infusion
prevented this effect, implying that IL-10 is able to regulate vascular
smooth muscle contraction and to partially prevent Ang II actions.
Smoothmuscle cells contain Ca2+-independentmechanisms to reg-
ulate contractility. The process of force generation is mediated by myo-
sin light chain kinase (MLCK) activation, and subsequent actin-myosin
cross-bridging, but the process of force maintenance is mediated in a
Ca2+-independent manner, and the RhoA/Rho kinase pathway has
been directly linked to this event [12,13]. Indeed, the increased vascular
reactivity in Ang II-induced hypertension is associated with enhanced
activation of the RhoA/Rho-kinase signaling pathway [15,16]. Rho-
kinase antagonist Y-27632 lowers blood pressure in several rat models
of experimental hypertension [13]. In addition, increased expression of
Rho-kinase protein in blood vessels from hypertensive rats has been
demonstrated [17–19]. Therefore, we focused our attention to investi-
gate if IL-10 plays a modulatory role in the RhoA/Rho kinase pathway
during Ang II-induced hypertension.
In our study, Rho-kinase inhibition abolished augmented contractile
response in aortas frommice infusedwith Ang II and IL-10, compared to
vehicle and also reduced the differences between IL-10 knockout mice
infused with or without Ang II, suggesting that IL-10 may negatively
regulates the activation of the RhoA/Rho-kinase pathway. These data
is supported by our molecular experiments, where we found that in
mice aorta, IL-10 negatively modulates RhoA and Rho-kinases expres-
sion, upon Ang II-stimulation.
On the top of modulating the activation of the RhoA/Rho-kinase
pathway on vascular smooth muscle cells and endothelial cells [14], it
is possible that IL-10 also regulates other pathways that are over activat-
ed during Ang II hypertension. IL-10 may be acting directly on inﬂam-
matory circulating cells, decreasing their activation and therefore
contributing to decreased production of pro-inﬂammatory cytokines.
In this regard, it is well known that during hypertension, inﬂammatory
cells, including macrophages and neutrophils, inﬁltrate the vasculature
and generate local inﬂammatory response, further contributing to vas-
cular dysfunction [20].
One additional possible mechanism by which IL-10, in part, regu-
lates Ang II-induced hypertension is that IL-10 is produced after pro-
inﬂammatory mediators, such as IL-6 and TNF-α and therefore, IL-10
has an important function to prevent and limit an excessive response
[21–23]. Cytokines appears to modulate blood pressure also in the cen-
tral neuron system level. It was recently shown that IL-10 is able to re-
duce the excitation of hypothalamic neurons induced by Ang II, by
inducing IKv currents [24,25]. The disruption of the balance between
anti- and pro-inﬂammatory cytokines alsomodulates vascular function,
and therefore, inﬂuencing blood pressure control [26].
In summary, we showed that endogenous and exogenous IL-10
counteracts both the pressoric activity and vascular dysfunctionassociated with Ang II-induced hypertension. Since the principal func-
tion of IL-10 is to limit and terminate inﬂammatory responses, it may
also provide a novel therapeutic target for the treatment of hyperten-
sion andwe propose that strategies to elevate IL-10maywork synergis-
tically with existent therapies to improve the outcome of hypertension.Acknowledgments
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